Neil Dahiya

DURECT Corporation, an advanced biopharmaceutical company at the forefront of creating epigenetic therapies for severe and critical medical conditions like acute organ injury, has finalized the sale of its Alzet osmotic pump product line to Lafayette Instrument Company (LIC). LIC, […]

Sartorius Stedim Biotech, a key player supporting the biopharmaceutical sector, has inaugurated its cutting-edge Center for Bioprocess Innovation in Marlborough, Massachusetts. This avant-garde space is designed to enhance teamwork, co-development, and on-site education with clients and external innovation partners, utilizing

Merck, referred to as MSD outside the U.S. and Canada, disclosed today successful topline findings from the Phase 3 ZENITH trial examining Winrevair (sotatercept-csrk) in adults diagnosed with pulmonary arterial hypertension (PAH, WHO Group 1), classified as functional class (FC)

Adragos Pharma, an internationally recognized contract development and manufacturing organization (CDMO) based in Munich, Germany, has acquired Baccinex, a Swiss expert known for its proficiency in aseptic fill-finish manufacturing. This acquisition significantly bolsters Adragos’ capabilities in sterile manufacturing and signifies

The recently concluded 2024 Super-Speciality Lens Symposium in Mumbai marked a pioneering moment in the fields of ophthalmology and optometry, drawing esteemed global experts and visionaries to discuss ground-breaking advancements in vision care. With insightful presentations from world-renowned authorities including

New York’s OverT Bio, a pioneering biotech firm focused on the creation of effective and secure cellular therapies for solid tumors, has proudly declared its receipt of a $120,000 G-Rex Grant. This funding comes from ScaleReady, in partnership with Wilson

At the upcoming 66th edition of the American Society of Hematology’s Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium, Novartis plans to unveil insights from over 65 abstracts, encompassing numerous investigator-led studies. “By emphasizing research in

Roche has announced that the US Food and Drug Administration (FDA) has authorized an expansion of its label to include the use of the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test for biliary tract cancer (BTC). This test stands

Promising outcomes from the CAPItello-281 phase III study reveal that AstraZeneca’s Truqap (capivasertib) alongside abiraterone and androgen deprivation therapy (ADT) yielded a statistically significant and clinically notable enhancement in radiographic progression-free survival (rPFS) compared to abiraterone and ADT with a

GSK plc has disclosed that the United States Food and Drug Administration (FDA) has agreed to review the Biologics License Application (BLA) for Blenrep (belantamab mafodotin) when combined with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]).